PARSIPPANY, NJ--(Marketwire - April 15, 2009) - The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 29, 2009 at 8:30 a.m. Eastern Time to discuss first quarter 2009 financial results and operational developments.
The conference call will be available via phone and webcast. The dial in information is listed below:
Domestic Dial In: 800-706-7745 International Dial In: 617-614-3472 Passcode for both dial in numbers: 34239136
Replay is available from 11:30 a.m. Eastern Time following the conference call through May 13, 2009. To hear a replay of the call, dial 888-286-8010 (domestic) and 617-801-6888 (international). Passcode for both dial in numbers is 33236910.
This call is being webcast and can be accessed at The Medicines Company website at www.themedicinescompany.com.
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment
of critical care patients through the delivery of innovative,
cost-effective medicines to the worldwide hospital marketplace. The Company
markets Angiomax® (bivalirudin) in the United States and other countries
for use in patients undergoing coronary angioplasty, and Cleviprex®
(clevidipine butyrate) injectable emulsion in the United States for the
reduction of blood pressure when oral therapy is not feasible or not
desirable. The Company also has an investigational antiplatelet agent,
cangrelor, in late-stage development and a serine protease inhibitor,
CU2010, in early-stage development. Through the acquisition of Targanta
Therapeutics, The Medicines Company's pipeline also includes oritavancin, a
semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory
approval. The Medicines Company's website is www.themedicinescompany.com.
